Eye shielding during @entity348 for bone marrow transplantation in @entity1 transplanted for a XXXX : risks and benefits.

@entity1 @entity231 @entity1503 @entity735 @entity348
This is a retrospective analysis of 188 @entity1 who underwent @entity348 ( @entity348 ) in one or two fractions before bone marrow transplantation (BMT) for a @entity1503 . While 139 @entity1 had eye shielding during @entity348 to decrease @entity231 formation, 49 did not. The blocks used for shielding caused cylindrical areas of decreased dose intensity in the brain. The aim of the study was to determine if there was an increased risk of @entity735 or in the CNS after shielding of the eyes. The probability and severity of @entity231 formation with and without shielding were also evaluated. None of the 49 @entity1 without shielding had a relapse in their eyes or in the CNS after BMT. Of the @entity1 with shielding, none had a @entity735 but two of the 139 (1.4%) had a CNS relapse. The incidence of @entity231 without shielding was 90% (19 of 21 evaluable @entity1 ), while with shielding it was 31% (20 of 64). Severe @entity231 were present in eight of 21 (38%) @entity1 without and two of 64 (3%) @entity1 with shielding. The probability of staying @entity231 free for at least five years was 0.77 with and 0.33 without shielding, at 8 years it was 0.53 and 0.24 respectively. The relative risk of developing a @entity231 without shielding vs shielding was three (95% CI=1.5; 5.9). It appears that the incidence of @entity735 and CNS is not increased when the eyes are shielded during @entity348 . Shielding increased the latency time of @entity231 formation and decreased the severity of @entity231 .
